Navigation Links
DrugRisk Update: Evidence Submitted in Actos Lawsuit Suggests Drug Maker Knew of Cancer Risks
Date:3/19/2013

New York, NY (PRWEB) March 19, 2013

The prescription drug resource center DrugRisk.com is alerting patients who have taken the drug Actos of updated legal news on the site. The resource site learned this week of new evidence showing the manufacturer may have known of the risks of bladder cancer in 2003, but did nothing to warn patients.

“The goal of DrugRisk is to improve consumer safety by publishing the latest drug warnings, recalls, studies and litigation news. Informed patients can discuss options with their doctor and decide if they need legal advice,” explains DrugRisk representative Ryan Mayer.

The resource center contains Actos warnings from both the FDA* and European Medicines Agency** who indicated that long-term use of the drug may be associated with an increased risk of bladder cancer. The drug has also been banned in France and Germany.***

In legal news, Takeda, the maker of Actos faces as many as 3,000 claims over Actos bladder cancer.**** More than 1,200 patients have filed an Actos lawsuit against the drug maker in a special multi-district federal court in Louisiana.***** Other cases have been filed in California.****

The first Actos trial began this month in California. Now, DrugRisk has learned that lawyers representing a man dying of cancer in that trial filed a study on January 25th which shows Takeda asked doctors in 2003 if they would still prescribe a diabetes drug that had bladder cancer risks. However, they didn’t disclose their concerns to patients.****

Lawyers are still helping those affected file claims. Anyone diagnosed with bladder cancer after taking Actos is urged to contact the DrugRisk Resource Center or speak with a lawyer about their legal rights as soon as possible.

Due to the specialized nature of defective drug injury cases, DrugRisk only recommends lawyers and law firms who have already handled Actos lawsuits.

For more information on the research, side effects, litigation news and a potential Actos recall or to speak with a lawyer, visit http://www.DrugRisk.com.

*fda.gov/ForConsumers/ConsumerUpdates/ucm263431.htm#Actos
**http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/07/news_detail_001311.jsp&mid=WC0b01ac058004d5c1
***cbsnews.com/8301-504763_162-20070492-10391704.html
****businessweek.com/news/2013-02-15/takeda-worried-about-actos-s-cancer-link-filing-shows
***** In Re: Actos Products Liability Litigation, MDL 2299, U.S. District Court, Western District of Louisiana (Lafayette).

Read the full story at http://www.prweb.com/releases/actos-recall/actos-lawsuits/prweb10491110.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisk Update: Bayer Discloses $500 Million Remaining for Yaz Lawsuits
2. DrugRisk Pradaxa Update: Litigation Grows As New Study Adds to Risks
3. DrugRisk Pradaxa Lawsuit Update: Court Denys Boehringer’s Protective Order Request
4. DrugRisk Update: Court Allows Charges of Prior Fraud Into Pradaxa Lawsuit
5. DrugRisk Update: NuvaRing Lawsuit Trials to Begin This Year
6. DrugRisk Announces New Pradaxa Health Warning From Australia
7. DrugRisk Adds Latest Health Warnings and Lawsuit Updates for Yaz
8. DrugRisk Announces Updated Information on Mirena Lawsuits
9. DrugRisk Announces Alternative to Mirena IUD May Be Available Soon
10. DrugRisk Center Announces Court Postponement of NuvaRing Lawsuits
11. Update: Number of Stryker Rejuvenate Hip Recall Lawsuits Growing in New Jersey Multicounty Litigation, Announces Wright & Schulte LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... VA (PRWEB) , ... February 17, 2017 , ... ... the Steps to Prevent a Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 ... , Do manufacturers distinguish between corrective action (CA) and preventive action (PA)? , ...
(Date:2/17/2017)... ... February 17, 2017 , ... Access today ... Exhibition in Orlando, Fla., February 19-23. Visitors to the company’s booth (#1778) will ... used electronic patient signatures solution in healthcare . , Since it first ...
(Date:2/17/2017)... ... February 17, 2017 , ... MAP ... today that Karen Pilley has been promoted to Chief Executive Officer. , ... healthcare paradigm – a shift that demands the transition from pay-for-service to pay-for-performance ...
(Date:2/17/2017)... ... 17, 2017 , ... PrideStaff, a national staffing organization, is ... Staffing Industry Analysts' 2017 "Staffing 100 North America" list. , Now in ... to the staffing industry over the last twelve months. Industry insiders and observers ...
(Date:2/17/2017)... ... ... Like most hospitals across the nation, Onslow Memorial Hospital is looking for ... Reduction Program (HRRP), the return of a patient to the hospital within 30 days ... many providers are struggling to leverage limited resources and technology, Onslow Memorial Hospital has ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... NEW YORK , Feb. 17, 2017  Noble ... coverage on ESSA Pharma Inc. (Nasdaq: EPIX ... Biotechnology Research, Kumar Raja , PhD. ... treatments for castration resistant prostate cancer (CRPC). Its lead ... selectively blocks the amino-terminal domain of the androgen receptor, ...
(Date:2/16/2017)... Quest Diagnostics (NYSE: DGX ), ... announced that it has been named one of the ... The annual survey designated Quest Diagnostics as ... Pharmacy and Other Services" industry to attain Most Admired ... attain the designation. This is the second consecutive year ...
(Date:2/16/2017)... , Feb. 16, 2017  Aralez Pharmaceuticals Inc. ... specialty pharmaceutical company, today announced that executive management will ... to be held February 22-23, 2017. Adrian Adams ... the Company at 1:35 p.m. local time on Wednesday, ... audio archive for the event may be accessed from ...
Breaking Medicine Technology: